Featuring latest Drug Developments and Treatment Protocols and also Updates about the Pharmaceutical Industry , both in Thailand and abroad, latest USFDA and Thai FDA approvals and also Corporate News with regards to various Pharma companies.
The US Food and Drug Administration approved Novartis AG's Adakveo (crizanlizumab) as new medicine that can help reduce extremely painful sickle cell disease flare-ups for patients 16 and older. The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly US$82,000 to US$114,000 per year, depending on dosing.
Unfortunately, sickle cell dise...
The US FDA approved a record-breaking 59 novel drugs in 2018 for a range of diseases, bringing hope to scores of health sufferers around the world. This number was a more than twofold increase from a decade prior, which saw only 24 new drug approvals. And while this rise in the production and dissemination of new biological agents and products is good news for the advancement of global h...
The U.S. Food and Drug Administration has granted approval for Reblozyl (luspatercept-aamt) to be used for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Dr Richard Pazdur, M.D., director of the US FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in th...
New findings from the LIBERTY ASTHMA QUEST trial show that add-on dupilumab (Dupixent) showed symptomatic benefit for patients with both early-onset and later-onset uncontrolled asthma.
In trial data published in the Chest Journal, the interleukin 4 and 13 (IL-4; IL-13) targeting monoclonal antibody showed an associated reduction of severe exacerbations and improved lung function in patien...
The US FDA has approved a new indication for the SGLT2 inhibitor canagliflozin made by Janssen Pharmaceuticals to reduce the risk for end-stage renal disease, worsening of kidney function, cardiovascular death and hospitalization for heart failure among adults with type 2 diabetes and diabetic kidney disease. Type 2 diabetes is the leading cause of kidney disease in the world, and the fifth fastes...
Trikafta (elexacaftor/ivacaftor/tezacaftor) from Vertex Pharmaceuticals is the first triple combination therapy to be approved by the US FDA and made available to treat patients with the most common cystic fibrosis mutation. Its list price is US$350,000 a year, same as one of the maker's earlier treatments for the genetic disease.
Trikafta has been approved for patients aged 12 an...
A study by the London School of Hygiene & Tropical Medicine has shown that Tranexamic Acid, a low cost and widely available drug could reduce deaths in traumatic brain injury patients by as much as 20%, depending on the severity of injury. The findings were published in the The Lancet. The researchers say that tranexamic acid, (TXA), a drug that prevents bleeding into the brain by inhibit...
A new flu drug by Genentech, Xofluza (baloxavir marboxil) has been granted US Food and Drug Administration (FDA) approval for a supplemental New Drug Application (NDA).
The US FDA approval has been given for the indication of acute, uncomplicated influenza, or flu, in individuals aged 12 and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-rela...
New study shows that ranitidine is an unstable molecule that breaks down under different conditions into the carcinogen N-nitrosodimethylamine (NDMA).
Online pharmacy Valisure is claiming that the Zantac is carcinogenic with N-nitrosodimethylamine (NDMA); that is a byproduct of the breakdown of the ranitidine molecule. The company, which performs its own testing on drugs it carries,...
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have discovered that Nilotinib (Tasigna), a drug used to treat chronic myeloid leukemia (CML) appears to be more effective at stopping a type of brain cancer called medulloblastoma in animal models than existing treatments for the deadly pediatric brain tumor.
Nilotinib is a type...
